Substrate-selective COX-2 inhibition as a novel strategy for therapeutic endocannabinoid augmentation

Highlights • Endocannabinoid augmentation may have broad therapeutic implications. • COX-2 is a third endocannabinoid metabolic mechanism. • Substrate-selective COX-2 inhibition increases central endocannabinoid signaling. • Substrate-selective COX-2 inhibition decreases anxiety.

Saved in:
Bibliographic Details
Published inTrends in pharmacological sciences (Regular ed.) Vol. 35; no. 7; pp. 358 - 367
Main Authors Hermanson, Daniel J, Gamble-George, Joyonna C, Marnett, Lawrence J, Patel, Sachin
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.07.2014
Subjects
Advanced Basic Science
Animals
Cannabinoids - metabolism
Cyclooxygenase 2 - metabolism
Cyclooxygenase 2 Inhibitors - pharmacology
Humans
Signal Transduction - drug effects
Substrate Specificity
Online AccessGet full text

Cover

More Information
Summary:Highlights • Endocannabinoid augmentation may have broad therapeutic implications. • COX-2 is a third endocannabinoid metabolic mechanism. • Substrate-selective COX-2 inhibition increases central endocannabinoid signaling. • Substrate-selective COX-2 inhibition decreases anxiety.
ISSN:0165-6147
1873-3735
DOI:10.1016/j.tips.2014.04.006